CDT Equity Inc. (NASDAQ:CDT) Sees Large Increase in Short Interest

CDT Equity Inc. (NASDAQ:CDT) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 277,728 shares, a growth of 305.9% from the January 15th total of 68,415 shares. Currently, 18.5% of the company’s shares are short sold. Based on an average trading volume of 601,455 shares, the short-interest ratio is presently 0.5 days. Based on an average trading volume of 601,455 shares, the short-interest ratio is presently 0.5 days. Currently, 18.5% of the company’s shares are short sold.

CDT Equity Stock Down 5.5%

NASDAQ:CDT opened at $1.04 on Friday. CDT Equity has a 52 week low of $0.91 and a 52 week high of $220.64. The stock’s fifty day moving average is $1.42 and its two-hundred day moving average is $4.85. The stock has a market capitalization of $1.70 million, a price-to-earnings ratio of 0.00 and a beta of 1.80.

CDT Equity (NASDAQ:CDT) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($13.16) earnings per share for the quarter.

Institutional Trading of CDT Equity

A hedge fund recently bought a new stake in CDT Equity stock. Apollon Wealth Management LLC acquired a new stake in CDT Equity Inc. (NASDAQ:CDT) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned approximately 28.28% of CDT Equity as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 3.29% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.